# **D LEARNING**

# How to Navigate the Future Parallel HTA and EMA Processes in the EU

**Virtual Live Training Course** 17-18 September 2025 | 14:00-18:30 CEST



# Overview

The first Joint Clinical Assessment (JCA) submissions under the HTA Regulation are underway. For new cancer medicines and ATMPs, since January this year the Regulatory submissions through the centralised procedure to the European Medicines Agency (EMA) will also trigger the JCA process. Both processes will run in parallel and the new legislative framework for exchange of information between regulators and HTA will take effect. The new process will require a close collaboration between the regulatory and HTA/market access teams at company level.

This course will discuss regulatory preparedness for the JCA process, explain the interface between regulators and EU HTA Coordination Group and which information is shared by the two.

It will inform you about practical strategic and operational challenges and how to solve them. Preparation early on in development is key, hence two workshops in small groups will focus on the role of prospective evidence planning/Joint Scientific consultation and the operational aspects of writing and submitting the JCA dossier.

The instructors have been very close to the HTA Regulation implementation activities in companies and with the policymakers.

# Learning Objectives

- Understand the JCA process and how it links to the marketing authorisation
- Regulatory documents or information shared to inform scoping process and JCA timelines
- Reducing the risk of the regulatory process to impact the JCA process
- Preparing and aligning internally
- Understand the role of prospective evidence planning/Joint Scientific consultation
- The operational aspects of writing and submitting the JCA dossier

# Who Will Attend

- Regulatory strategy leads
- Regulatory authority members
- Clinical development professionals
- CROS
- Consultants involved in EMA's approval processes

# **Faculty**

### **Isabelle Stoeckert**

Independent Regulatory Science Expert

# Inka Heikkinen

Regulatory Policy Lead, Lundbeck

# **Nadege Le Roux**

Senior Director, Regulatory Policy & Intelligence, BMS

### **Thomas Ecker**

CEO. Ecker + Ecker GmbH

# **Anke van Engen**

Global Category Leader, Health Economics, HTA. Value and Access. IQVIA



# DAY 1

### 14:00 WELCOME AND INTRODUCTION

14:15 SESSION 1 PART 1

### JCA LEGISLATIVE FRAMEWORK AND GUIDELINES

# Inka Heikkinen

- Introduction to HTA Regulation and implementing acts
- The HTA JCA process and how it relates to EU Marketing **Authorisation Application process**
- Rules for exchange of information between the EMA and EU HTA Coordination Group, and its subgroups

# 15:00 SESSION 1 PART 2

### JSC FRAMEWORK AND PROCESS

### Inka Heikkinen

- JSC regulatory framework
- Application process and tips for the application form
- Learnings from previous parallel advice

# 15:30 DISCUSSION AND Q&A

#### **BREAK** 15:45

### 16:00 SESSION 2

# IMPLICATIONS FOR REGULATORY STRATEGY AND ENGAGEMENT **PLAN**

# Isabelle Stoeckert

- Regulatory relevant aspect of the JCA dossier (PICO concept and dossier content)
- Label considerations and scenario planning
- · Narrative alignment and managing the parallel process
- Transparency of the JCA dossier and potential implications

# 17:00 SESSION 3

# INTERNAL ALIGNMENT AND COMMUNICATION AS THE **CORNERSTONE FOR SUCCESS**

# Nadege Le Roux

· Reducing uncertainties through close communication of timelines, anticipated questions and final indication

# 18:00 DISCUSSION AND QUESTIONS

# 18:30 END OF DAY 1

# DAY 2

### 14:00 WELCOME AND RECAP

#### SESSION 4 14:15

### JCA DOSSIER - WHAT GOES IN IT?

# Thomas Ecker

- Specifications of the JCA dossier
- · Similarities with the AMNOG dossier
- · Common and different elements to the regulatory dossier
- Guidances

# 15:00 SESSION 5

# **EVIDENCE GENERATION - ADDRESSING THE POSSIBLE GAPS**

# Anke van Engen

- · Learnings from the PICO simulations & required evidence
- · Overview of non-direct evidence approaches and acceptable methods

#### 15:45 **BREAK**

### 16:00 SESSION 6

# **GROUP DISCUSSIONS**

Group A: JCA DOSSIER AND PICO ANTICIPATION

Moderation: Thomas Ecker and Inka Heikkinen

Group B: EVIDENCE GENERATION AND ADVICE

Moderation: Anke van Engen and Nadege Le Roux

# 18:00 CLOSING OF THE COURSE

- · Recap from the discussions
- Contribute to a learning system
- · Outlook on future development what can be expected from the policymakers?
- · Remaining questions

# 18:30 END OF THE TRAINING COURSE

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.



# **Group Discounts**

Register 3 individuals from the same company for the same course and receive complimentary registration

To take advantage of this offer, please print the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together via email to basel@diaglobal.org.

\*Terms and Conditions apply. Please contact DIA EMEA office for more information.



# Customized Professional Development for Your Team

Get a customized training for your department (or even across different departments!) and benefit from increased:

- · Knowledge of a topic of your choice
- · Flexibility & Convenience
- Cost Effectiveness

Or explore eLearning to allow self-paced learning.

For more information please contact <a href="mailto:basel@diaglobal.org">basel@diaglobal.org</a>



# **About DIA**

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China



# Technical Requirements

To test your system compatibility, please click on the link: https://diaglobal.zoom.us/test

For further information on system requirements, please visit the website: https://www.diaglobal.org/General/System-Requirements



# **Continuing Education**

Please note: Most EU countries accept direct submission, by the participant, of training courses, conferences and other educational opportunities with the aim of obtaining CPD (Continuous Professional Development) points. Please do not hesitate to contact DIA directly if you need any further documentation to conclude your submission.

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 7 credits.



# **REGISTRATION FORM**

HTAR | Virtual Live Training Course | # 25590 17-18 September 2025 | 14:00-18:30 CEST



### **REGISTRATION FEES**

Registration fee includes full admission to virtual course, electronic access to training course materials. Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material. Please check:

FEES	MEMBER EARLY-BIRD valid until 23 Jul 2025	MEMBER valid from 24 Jul 2025	NON- MEMBER
INDUSTRY/ REPRESENTATIVE	€ 900.00 □	€ 1′000.00 🗖	€ 1′260.00 🗖
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	NA	€ 500.00 □	€ 760.00 □

A special discount is available for organisations which are listed in the <u>EMA SME register</u>. Number of discounted seats are limited.

All registration	fees are sub	ject to VA1	「if applicable.
------------------	--------------	-------------	-----------------

Please enter your company's VAT number:

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

Payment is due 30 days after registration and must be paid in full by commencement of the course.

### DIA MEMBERSHIP

All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at DIAqlobal.org/Membership.

DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at <a href="DIAglobal.org">DIAglobal.org</a>. If you would like to decline complimentary membership, please indicate your preference below.

☐ I would like to decline a one year complimentary DIA membership.

The DIA Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 09:00 and 17:00 CE(S)T. Tel.:+41 61 225 51 51

Email: <u>Basel@DIAglobal.org</u> Mail: DIA, Küchengasse 16, 4051 Basel, Switzerland Web: www.DIAglobal.org

### TERMS AND CONDITIONS

### **Cancellation Policy**

All cancellations must be made in writing and be received at the DIA office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

If you do not cancel four weeks prior to the event start date and do not attend, you will be responsible for the full registration fee.

DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

# Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA office of any such substitutions as soon as possible.

### Event Stream and Recording

If you attend a DIA event, we make video and audio recordings of events (both face-to-face and online) that may include your participation in the event, including your image, questions and comments.

To view our full photography and video recording policy, click <a href="https://www.diaglobal.org/general/">https://www.diaglobal.org/general/</a>
photography-policy.

# Privacy Policy

DIA respects the privacy of all of its members and customers. To view our privacy policy, click https://www.diaglobal.org/about-us/privacy-policy.

# **ATTENDEE DETAILS** PAYMENT METHOD Please complete in block capital letters or attach the attendee's business card here. DIA accepts only Credit Card as a payment method. ☐ Prof ☐ Dr ☐ Ms ☐ Mr Payments by VISA, Mastercard or AMEX are accepted. Other types of credit card are not accepted. Last Name You will receive a payment link in the coming days to complete the Please complete payment within 7 days of receipt of the payment First Name Payments will be net of all charges and bank charges will be Job Title borne by the payer. Company If you have not received your confirmation within five working days, please contact basel@diaglobal.org. Address By signing below, I confirm that I read and agree with DIA's Terms and Conditions of booking. Postal Code These are available from the office or online by clicking: http://www.diaglobal.org/EUterms Country Date Signature Telephone Number